In a phase I clinical trial, PRS-343 demonstrated antitumor activity as a single agent and in combination with the anti-PD-L1 antibody atezolizumab in previously treated patients with advanced HER2-positive solid tumors (including GC) [62]. This evidence concerns the gene CD274 and gastric cancer.